Prothena Reports First Quarter 2014 Financial Results and Provides R&D Updates
GlobeNewswire - Mon May 05, 3:39PM CDT
-- Encouraging cardiac biomarker responses from ongoing Phase 1 of NEOD001 in patients with AL amyloidosis and persistent organ dysfunction presented at ISA
Prothena to Host Webcast and Conference Call to Discuss Interim Phase 1 Data of Ongoing NEOD001 Study in Patients With AL Amyloidosis on May 2
GlobeNewswire - Thu May 01, 3:12PM CDT
Prothena Corporation plc (Nasdaq
Prothena Announces Appointment of Chief Legal Officer
Thomson Reuters ONE - Wed Apr 30, 3:31PM CDT
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
Prothena Corporation plc (PRTA) Worth Watching: Stock Rises 9.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:44AM CDT
Prothena Corporation plc (PRTA) was a big mover last session, as the company saw its shares rally nearly 10.00% on the day.
Why Prothena (PRTA) Stock Is Up Today
at The Street - Wed Apr 23, 2:39PM CDT
Prothena (PRTA) shares are up following the publishing of an abstract touting its AL amyloidosis treatment
Prothena's NEOD001 Demonstrates Encouraging Cardiac Biomarker Responses in Ongoing Phase 1 Study in Patients With Immunoglobulin Light Chain (AL) Amyloidosis
Thomson Reuters ONE - Wed Apr 23, 10:59AM CDT
- NEOD001 appears generally safe, well-tolerated, has acceptable pharmacokinetic properties and no immunogenicity at studied dose levels
Strategic Collaborations, Preclinical Studies Results, Patient Enrollment, Earnings Release Schedule, and Clinical Trial Initiations - Analyst Notes on Pacira, Celldex, Aegerion, Furiex, and Prothena
PR Newswire - Mon Apr 14, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Celldex Therapeutics, Inc. (NASDAQ: CLDX), Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR), Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) Prothena Corporation plc (NASDAQ: PRTA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1035-100free
Why Prothena Corporation PLC Shares Leaped Higher
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 09, 1:03PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Prothena , a clinical-stage...
Pipeline Progress at Prothena - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 11:00AM CDT
Prothena Corporation (PRTA) has initiated a randomized, double-blind, placebo-controlled phase I trial on its monoclonal antibody candidate, PRX002.
First Human Dosed in Phase 1 Study of PRX002 for Treatment of Parkinson's Disease
Thomson Reuters ONE - Tue Apr 08, 3:06PM CDT
- Entering clinic triggers $15 million milestone payment from Roche
3 Warning Signs the Biotech Rally May Be Over
Sean Williams, The Motley Fool - Motley Fool - Tue Mar 25, 11:10AM CDT
Yes, despite contrary belief, biotech stocks can actually go down just as they've been going up, and up, and up some more over the past couple of years. Friday's tumble in the SPDR S&P Biotech ETF on the heels of congressional probing into...
Healthcare Companies Report Acquisitions, Upcoming Results Schedules, Dividends, and Annual Reviews - Analyst Notes on Pfizer, Magellan Health Services, Prothena, Alere, and KYTHERA
PR Newswire - Fri Mar 21, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Pfizer Inc. (NYSE: PFE), Magellan Health Services Inc. (NASDAQ: MGLN), Prothena Corporation plc (NASDAQ: PRTA), Alere Inc. (NYSE: ALR), and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Prothena Surges on Clinical Data Hopes - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 10:00AM CDT
Prothena Corporation surged after the company announced that data from a phase I study on NEOD001 will be presented at the ISA.
Prothena (PRTA) Jumps: Stock Rises 27.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 7:57AM CDT
Prothena Corporation plc (PRTA) was a big mover last session, as the company saw its shares rise over 27% on the day.
Why Prothena, Galena Biopharma, and Horizon Pharma Are Today's 3 Best Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 19, 4:15PM CDT
Janet Yellen's first chaired Federal Open Market Committee meeting was certainly a memorable one, with the broad-based S&P 500 hiccuping and heading lower after the FOMC announced its latest policy decisions. According to Yellen, the...